# triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE

Study · id `cardio:ct-nct07440381` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07440381](<https://clinicaltrials.gov/study/NCT07440381>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07440381

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07440381. Randomized; no masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2027-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07440381, source copy `cardio:ctgov-nct07440381-2026-02-27`, retrieved 2026-10-31)
- Planned start: 2026-09 (anticipated) (ClinicalTrials.gov record NCT07440381, source copy `cardio:ctgov-nct07440381-2026-02-27`, retrieved 2026-10-31)
- Primary completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT07440381, source copy `cardio:ctgov-nct07440381-2026-02-27`, retrieved 2026-10-31)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT07440381, source copy `cardio:ctgov-nct07440381-2026-02-27`, retrieved 2026-10-31)
- Countries: Italy (ClinicalTrials.gov record NCT07440381, source copy `cardio:ctgov-nct07440381-2026-02-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07440381-2026-02-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
- Acronym: PERSUADE
- Condition: Acute Coronary Syndromes
- Condition: Secondary Prevention
- Condition: Lipids
- Intervention (Drug): Triple oral lipid lowering treatment
- Lead sponsor: Heart Care Foundation
- Lead sponsor class: OTHER
- Collaborator: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as a collaborator: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (`cardio:org-daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company`)

## Provenance

Content hash: 41a5548a0f4df68fedfd66ea1b14068a2c9c73ce729058bab433e1a1ea13e989
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
